

PAKISTAN STOCK BROKERS ASSOCIATION

(A company setup under section 42 of the Companies Act 2017)

Regd Office: Mezzanine Floor, Trading Hall, Stock Exchange Building, Stock Exchange Road,

Off I.I Chundrigar Road, Karachi.

Tel: 021-32401278, E-mail: secretariat@psba.pk, Web: www.psba.pk, Fax: 021-32401279

PSBA/Notice-188

November 12, 2024

NOTICE FOR MEMBERS

PROPOSED AMENDMENTS IN THE SCHEDULE OF FEES & DEPOSITS

This is in reference to the notification CDC/C/N/05/2024 dated November 11, 2024 (attached), whereby the comments have been invited by the CDC:

In this regard, the members are hereby requested to kindly submit your comments, if any, at psamail024@gmail.com latest by **November 15**, **2024**, so that a consolidated response is submitted to the authorities for their consideration.

Sd

Akber Ali

Officer - Secretariat

Copy to:

1. PSBA Website



Central Depository Company of Pakistan Limited

Head Office: CDC House, 99-B, Block 'B', S.M.C.H.S., Main Shahra-e-Faisal, Karachi-74400

Ref. No. CDC/C/N/05/2024

November 11, 2024

Notification No. 05 of 2024

Sub: Proposed amendments in the Schedule of Fees & Deposits

To, The General Public,

This is to bring to the notice of general public that the Board of Directors of CDC in its drive to rationalize the tariff, has further reduced the Transaction Fee for GOP Ijara Sukuk. The proposed fee has now been limited to 0.0010% as against the current fee of 0.0036%. However, in case of one year GOP Ijara Sukuk, the fee will be charged on pro rata basis. This initiative will promote ease of doing business and will provide facilitation for investors of Government's Sukuk.

Accordingly, the amendments in the Schedule of Fees and Deposits approved by the CDC Board are enclosed herewith. As required under Section 51(2) of the Securities Act, 2015 (III of 2015), CDC has placed such amendments for soliciting public comments which may be submitted, in the manner as suggest in the "Guidelines for Submission of Comments", within 7 days of this Notification i.e. by Monday, November 18, 2024.

Regards,

Hammad Ali Faisal Chief Compliance Officer

The Director/ HOD (PRDD-SMD)
Securities and Exchange Commission of Pakistan Islamabad

The Chief Executive OfficerNational Clearing Company of Pakistan Limited Karachi

The Chief Executive OfficerPakistan Stock Exchange Limited
Karachi

The Secretary General
Pakistan Stock Brokers Association
Karachi

UAN: 111-111-500 Email: info@cdcpak.com Help Desk: 0800-23275 Fax: (021) 34326036

THE CENTRAL DEPOSITORY COMPANY OF PAKISTAN LIMITED

FEES AND DEPOSITS SCHEDULE @

SCHEDULE OF FEES									
S. No.	NAME	RATE	BASIS	LEVIED ON	COLLECTION				
					WHEN	MODE			
2.	Transaction Fee - for Shares - for Redeemable Securities - for WAPDA Bonds ** - for Units*** - GOP Ijara Sukuk - for Rights Entitlements (unpaid rights)	0.0036% 0.0036% 0.0036% 0.0036% 0.0010% 0.0036%	(Note 2) Market value per transaction**** Market value per transaction**** Market value per transaction**** Quoted or offer price per transaction**** Market value per transaction*** Market value per transaction****	Participant/Account Holder	Month end (calculated on daily basis)	P.O./Draft/Cheque			

****** Closing market value of last trading session of every trading day at the Pakistan Stock Exchange Limited. In case of one year GOP Ijara Sukuk, the fee will be charged on pro rata basis which shall be calculated from transaction / trade date to maturity date.

UPDATED: NOVEMBER 2024

UPDATED: NOVEMBER 2024

Guidelines for Submission of Comments

1. CDC invites the interested parties to provide their comments and views, with specific reference to the subject matter of the proposed amendments to CDC Regulations notified via notices, through any of the following modes.

Email	comments@cdcpak.com		
Mail	The Chief Compliance Officer, Central Depository Company of Pakistan Limited CDC House, 99-B, Block 'B', S.M.C.H.S., Main Shahra-e-Faisal, Karachi-74400, Pakistan		

2. At the time of submission of comments, respondent is advised to provide the information, as per **Table-A** below, so that CDC may contact him/her for clarification or deliberation on the comments, if needed. Anonymous responses may be disregarded by CDC.

Table A

To Be Filed By The Respondent				
Name of respondent				
Account No.				
Name of company (if applicable)				
Designation (if applicable)				
Contact Number				
Email Address				

3. The respondent may request confidential treatment for his/ her identity and all or any part of comments due to their proprietary, confidential or commercial nature, by clearly marking the information in **Table-B** below:

Table B
Disclosure of Identity and Comments

Please check the box(es) if you wish to be remain confidential:				
I wish to have my identity remain confidential.				
I wish to keep all or any part of my comments confidential.				

If respondent wishes to keep any part(s) of comments confidential, then he/she is required to clearly specify such part(s) of comments.

- 4. To ensure quality and promote transparency, CDC will publish the relevant comments of respondents and its management's response thereon in the form of a Response Paper on its website, within a reasonable timeframe, after close of public consultation session, unless the respondent has made a confidentiality request.
- 5. Any policy or rule amendment may be subject to regulatory concurrence. For this purpose, respondents should note that notwithstanding any confidentiality request, CDC will share all their response(s) with the Securities and Exchange Commission of Pakistan (Apex Regulator).
- 6. By submitting comments, respondents are deemed to have consented to the collection, use and disclosure of data that is provided to CDC, unless respondents wish to have their identity or comments remain confidential.